107 related articles for article (PubMed ID: 29732688)
1. Restoration of natural killer cell activity by interferon-free direct-acting antiviral combination therapy in chronic hepatitis C patients.
Nakamura I; Furuichi Y; Sugimoto K
Hepatol Res; 2018 Oct; 48(11):855-861. PubMed ID: 29732688
[TBL] [Abstract][Full Text] [Related]
2. Restoration of natural killer cell activity by pegylated interferon-alpha/ribavirin therapy in chronic hepatitis C patient.
Nakamura I; Asano T; Asabe S; Ando M; Sano T; Miyata Y; Taira J; Sugimoto K; Imai Y; Moriyasu F; Imawari M
Hepatol Res; 2015 Jan; 45(1):107-12. PubMed ID: 24606027
[TBL] [Abstract][Full Text] [Related]
3. Direct antiviral agents upregulate natural killer cell potential activity in chronic hepatitis C patients.
Jiang HJ; Wang XX; Luo BF; Cong X; Jin Q; Qin H; Zhang HY; Kong XS; Wei L; Feng B
Clin Exp Med; 2019 Aug; 19(3):299-308. PubMed ID: 31218578
[TBL] [Abstract][Full Text] [Related]
4. Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir.
Wang XX; Luo BF; Jiang HJ; Cong X; Jin Q; Ma DL; Wei L; Feng B
World J Gastroenterol; 2018 Oct; 24(40):4554-4564. PubMed ID: 30386105
[TBL] [Abstract][Full Text] [Related]
5. [Effect of gMDSCs on natural killer cell functionality in chronic hepatitis C patients treated with direct-acting antiviral agents].
Shi JJ; Zhou WJ; Lu C; Jia XY; Chang WX; Zhang JY; Li YY; Mu XL
Zhonghua Yi Xue Za Zhi; 2021 Jul; 101(27):2133-2139. PubMed ID: 34275248
[No Abstract] [Full Text] [Related]
6. Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C.
Morio K; Imamura M; Kawakami Y; Nakamura Y; Hatooka M; Morio R; Fujino H; Nakahara T; Murakami E; Kawaoka T; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Miki D; Ochi H; Katamura Y; Arataki K; Moriya T; Ito H; Tsuji K; Kohno H; Waki K; Tamura T; Nakamura T; Chayama K;
J Med Virol; 2018 Dec; 90(12):1834-1840. PubMed ID: 30016555
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of interferon-free regimen for patients with genotype-1 HCV infection.
Takeda K; Noguchi R; Namisaki T; Moriya K; Akahane T; Kitade M; Kawaratani H; Shimozato N; Kaji K; Takaya H; Sawada Y; Seki K; Fujinaga Y; Tsuji Y; Kubo T; Sato S; Saikawa S; Nakanishi K; Furukawa M; Kitagawa K; Ozutsumi T; Kaya D; Mitoro A; Mashitani T; Okura Y; Yamao J; Yoshiji H
Exp Ther Med; 2018 Sep; 16(3):2743-2750. PubMed ID: 30210615
[TBL] [Abstract][Full Text] [Related]
8. Increased peripheral CD4
Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
[TBL] [Abstract][Full Text] [Related]
9. Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function.
Serti E; Chepa-Lotrea X; Kim YJ; Keane M; Fryzek N; Liang TJ; Ghany M; Rehermann B
Gastroenterology; 2015 Jul; 149(1):190-200.e2. PubMed ID: 25754160
[TBL] [Abstract][Full Text] [Related]
10. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
[TBL] [Abstract][Full Text] [Related]
11. Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction.
Geddawy A; Ibrahim YF; Elbahie NM; Ibrahim MA
J Transl Int Med; 2017 Mar; 5(1):8-17. PubMed ID: 28680834
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Hepatitis C Virus Infection in Dialysis Patients.
Kikuchi K
Contrib Nephrol; 2018; 196():119-122. PubMed ID: 30041215
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of occult hepatitis C virus infection in patients who achieved sustained virologic response to direct-acting antiviral agents.
Yousif MM; Elsadek Fakhr A; Morad EA; Kelani H; Hamed EF; Elsadek HM; Zahran MH; Fahmy Afify A; Ismail WA; Elagrody AI; Ibrahim NF; Amer FA; Zaki AM; Sadek AMEM; Shendi AM; Emad G; Farrag HA
Infez Med; 2018 Sep; 26(3):237-243. PubMed ID: 30246766
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study.
Itokawa N; Atsukawa M; Tsubota A; Ikegami T; Shimada N; Kato K; Abe H; Okubo T; Arai T; Iwashita AN; Kondo C; Mikami S; Asano T; Matsuzaki Y; Toyoda H; Kumada T; Iio E; Tanaka Y; Iwakiri K
Hepatol Res; 2019 Feb; 49(2):125-135. PubMed ID: 30307682
[TBL] [Abstract][Full Text] [Related]
15. Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment.
Spaan M; van Oord G; Kreefft K; Hou J; Hansen BE; Janssen HL; de Knegt RJ; Boonstra A
J Infect Dis; 2016 Jan; 213(2):216-23. PubMed ID: 26223768
[TBL] [Abstract][Full Text] [Related]
16. [Not Available].
Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Péter Z; Rókusz L; Schneider F; Szalay F; Tornai I; Werling K; Makara M
Orv Hetil; 2015 Dec; 156 Suppl 2():3-24. PubMed ID: 26667111
[TBL] [Abstract][Full Text] [Related]
17. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
Tada T; Kumada T; Toyoda H; Mizuno K; Sone Y; Kataoka S; Hashinokuchi S
J Gastroenterol Hepatol; 2017 Dec; 32(12):1982-1988. PubMed ID: 28299813
[TBL] [Abstract][Full Text] [Related]
18. Multitarget Direct-Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus.
Shrivastava S; Bhatta M; Ward H; Romani S; Lee R; Rosenthal E; Osinusi A; Kohli A; Masur H; Kottilil S; Wilson E
Hepatol Commun; 2018 Dec; 2(12):1451-1466. PubMed ID: 30556035
[TBL] [Abstract][Full Text] [Related]
19. Early and late changes in natural killer cells in response to ledipasvir/sofosbuvir treatment.
Golden-Mason L; McMahan RH; Kriss MS; Kilgore AL; Cheng L; Dran RJ; Wieland A; Rosen HR
Hepatol Commun; 2018 Apr; 2(4):364-375. PubMed ID: 29619416
[TBL] [Abstract][Full Text] [Related]
20. CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection.
Lin AW; Gonzalez SA; Cunningham-Rundles S; Dorante G; Marshall S; Tignor A; Ha C; Jacobson IM; Talal AH
Clin Exp Immunol; 2004 Aug; 137(2):408-16. PubMed ID: 15270860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
